CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2009-08-17): Histoplasmosis rare after solid organ transplants

Clinical

Histoplasmosis rare after solid organ transplants

Last Updated: 2009-08-17 17:00:06 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Even in endemic areas, few solid organ transplant recipients develop histoplasmosis, Ohio-based researchers report in the September 1st issue of Clinical Infectious Diseases.

Dr. S. D. Mawhorter and colleagues at the Cleveland Clinic note, however, that in part because of a lack of studies, there are few specific recommendations on the ideal treatment of histoplasmosis in organ recipients.

"The Ohio and Mississippi River valleys are known to be endemic for histoplasmosis since 1945," the researchers point out. To gain more information, they reviewed data on 3436 solid organ recipients transplanted at their institution from 1997 to 2007, 38 of whom were diagnosed with post-transplantation histoplasmosis. In 29 patients, laboratory confirmation of infection was documented.

Fourteen of these patients developed proven active histoplasmosis after transplantation of a heart, lung, kidney, liver or pancreas or a combined kidney-pancreas. All 14 had disseminated disease. The median time from transplantation to diagnosis was 17 months, and the median time from onset of symptoms to diagnosis was 3 weeks.

Eleven of these patients were initially treated with amphotericin B for a median of 23.5 days, and 9 were switched to itraconazole.

Another 10 patients had evidence of histoplasmosis in their explanted organ (9 lung recipients and 1 liver recipient who also required splenectomy for splenomegaly). Four patients received donor tissue evidence of histoplasmosis, and 1 had active histoplasmosis before transplantation.

The 14 patients with evidence of infection in their explant or their donor tissue received prophylaxis, and none developed active disease. The remaining patient, who had histoplasmosis before transplantation, was given itraconazole prior to and after the procedure.

All patients were cured or are still on therapy but free of symptoms, the researchers report.

Post-transplantation histoplasmosis is rare, the investigators conclude, being limited even in their endemic region to 1 case per 1000 transplant-person years. "Prognosis is good," they add, "but requires protracted therapy."

Clin Infect Dis 2009;49:710-716.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.